Mark Thursz

Mark Thursz

Imperial College London

H-index: 85

Europe-United Kingdom

About Mark Thursz

Mark Thursz, With an exceptional h-index of 85 and a recent h-index of 56 (since 2020), a distinguished researcher at Imperial College London, specializes in the field of Hepatology, Hepatitis, Alcoholic Liver Disease.

His recent articles reflect a diverse array of research interests and contributions to the field:

Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?

Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis

Unmasking the silent threat—acute kidney injury in alcohol‐associated hepatitis. Authors' reply

A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis

Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity

In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and …

Mark Thursz Information

University

Position

Professor of Hepatology

Citations(all)

25777

Citations(since 2020)

13208

Cited By

17287

hIndex(all)

85

hIndex(since 2020)

56

i10Index(all)

250

i10Index(since 2020)

191

Email

University Profile Page

Imperial College London

Google Scholar

View Google Scholar Profile

Mark Thursz Skills & Research Interests

Hepatology

Hepatitis

Alcoholic Liver Disease

Top articles of Mark Thursz

Title

Journal

Author(s)

Publication Date

Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?

Journal of Hepatology

Mark Thursz

Philippe Mathurin

2024/3/16

Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis

The Lancet global health

Liem B Luong Nguyen

Maud Lemoine

Gibril Ndow

Zachary J Ward

Timothy B Hallet

...

2024/1/1

Unmasking the silent threat—acute kidney injury in alcohol‐associated hepatitis. Authors' reply

Luke D Tyson

Stephen Atkinson

Robert W Hunter

Mark Thursz

Nikhil Vergis

2024/1

A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies

Liver International

Roberta Forlano

Tijana Stanic

Sahan Jayawardana

Benjamin Harvey Mullish

Michael Yee

...

2024/1

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

Gut Microbes

R Forlano

L Martinez-Gili

P Takis

J Miguens-Blanco

T Liu

...

2024/12/31

Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis

Journal for Immunotherapy of Cancer

Cathrin LC Gudd

Eoin Mitchell

Stephen R Atkinson

Marie-Anne Mawhin

Samra Turajlic

...

2024

Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity

EBioMedicine

Charlotte Hateley

Antoni Olona

Laura Halliday

Matthew L Edin

Jeong-Hun Ko

...

2024/5/1

In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and …

Alimentary pharmacology & therapeutics

Luke D Tyson

Stephen Atkinson

Robert W Hunter

Michael Allison

Andrew Austin

...

2023/12

Tu1866 SALIVARY MICROBIOTA COMPOSITION IS ASSOCIATED WITH ANTIBODY RESPONSE FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE, CIRRHOSIS AND LIVER …

Gastroenterology

Benjamin H Mullish

Nathan P Danckert

Ria Patel

Sophie L Irwin

Stavros Dimitriadis

...

2023/5/1

Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings

Clinical Gastroenterology and Hepatology

Yusuke Shimakawa

Gibril Ndow

Atsushi Kaneko

Katsumi Aoyagi

Maud Lemoine

...

2023/7/1

Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease

EBioMedicine

Trishan Vaikunthanathan

Emmanuelle Landmann

Diana Marin Correa

Marco Romano

Silvia Cellone Trevelin

...

2023/9/1

Advances in the understanding and management of alcohol-related liver disease

Mark Thursz

Anne Lingford-Hughes

2023/11/20

Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers

2023/4/20

The role of neutrophils in alcohol-related hepatitis

Reenam S Khan

Patricia F Lalor

Mark Thursz

Phil Newsome

2023/6/6

Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study

Blood Coagulation & Fibrinolysis

Yong Hoon Lee

Seung-Ick Cha

Kyung Min Shin

Jae Kwang Lim

Won Kee Lee

...

2021/9/1

Immune Checkpoint Inhibitor-Induced Liver Injury

Cathrin LC Gudd

Roosey Sheth

Mark R Thursz

Evangelos Triantafyllou

Lucia A Possamai

2023/11

Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community

Digestive and Liver Disease

R Forlano

T Stanic

S Jayawardana

BH Mullish

M Yee

...

2023/3/1

Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non …

Journal of Hepatology

Giordano Sigon

Roberta Forlano

Benjamin H Mullish

Jian Huang

Michael Yee

...

2023/6/1

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2

Journal of General Virology

Mark Thursz

Fuzia Sadiq

Julia A Tree

Peter Karayiannis

David WC Beasley

...

2023/7/11

O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease

Roberta Forlano

Miss Huma Malik

Giordano Sigon

Miss Vicky Lin

Jian Huang

...

2023/9/1

See List of Professors in Mark Thursz University(Imperial College London)